Shares of Athersys, which have nearly doubled in the past 3 months, should keep their momentum as a number of data points concerning the company's regenerative medicine treatments roll in, says Gil Van Bokkelen, CEO of Athersys. Van Bokkelen says the company's lead drug MultiStem is entering into a number of late stage clinical trials across a number of illnesses. He also says the company is making huge strides with patents in Japan and has successfully raised enough cash to carry it forward.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

More from Video

Jim Cramer: Advanced Micro Devices CEO Lisa Su Saved the Company

Jim Cramer: Advanced Micro Devices CEO Lisa Su Saved the Company

Jim Cramer Just Spoke to Larry Kudlow About the China Trade Negotiations

Jim Cramer Just Spoke to Larry Kudlow About the China Trade Negotiations

UPS CFO Discusses Plans to Boost Company's Stock Price

UPS CFO Discusses Plans to Boost Company's Stock Price

Facebook Just Announced a Major Share Buyback Program

Facebook Just Announced a Major Share Buyback Program

Veteran Foreign Affairs Expert Ian Bremmer Reveals How to Price Political Risk

Veteran Foreign Affairs Expert Ian Bremmer Reveals How to Price Political Risk